Sudarshan Pharma Industries Limited (BOM:543828)
India · Delayed Price · Currency is INR 35.47
+1.20 (3.50%)
At close: May 26, 2026
BOM:543828 Revenue
In the fiscal year ending March 31, 2026, Sudarshan Pharma Industries had annual revenue of 7.12B INR with 40.93% growth. Sudarshan Pharma Industries had revenue of 2.21B in the quarter ending March 31, 2026, with 36.71% growth.
Revenue
7.12B
Revenue Growth
+40.93%
P/S Ratio
1.26
Revenue / Employee
117.18M
Employees
60
Market Cap
8.86B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 7.12B | 2.07B | 40.93% |
| Mar 31, 2025 | 5.05B | 415.07M | 8.95% |
| Mar 31, 2024 | 4.64B | 22.10M | 0.48% |
| Mar 31, 2023 | 4.61B | 1.04B | 29.19% |
| Mar 31, 2022 | 3.57B | 1.64B | 84.52% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| TTK Healthcare | 8.30B |
| Anuh Pharma | 7.72B |
| Kopran | 6.81B |
| Wanbury | 6.58B |
| Fredun Pharmaceuticals | 6.39B |
| Fermenta Biotech | 5.48B |
| ZIM Laboratories | 3.74B |
| Bharat Parenterals | 3.45B |
Sudarshan Pharma Industries News
- 27 days ago - Sudarshan Pharma Industries Quarterly report: Q4 2026 - Filings
- 4 months ago - Sudarshan Pharma Industries Quarterly report: Q3 2026 - Filings
- 7 months ago - Sudarshan Pharma Industries Quarterly report: Q2 2026 - Filings
- 10 months ago - Sudarshan Pharma Industries Quarterly report: Q1 2026 - Filings